Home/News/Severe aplastic anemia and hypoplastic MDS focus of new clinical trial

Severe aplastic anemia and hypoplastic MDS focus of new clinical trial

The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor.

The study is being conducted by Richard W. Childs, M.D., clinical director of the National Heart, Lung and Blood Institute’s (NHLBI) Division of Intramural Research in the National Institutes of Health (NIH) and Assistant United States Surgeon General.

“Severe aplastic anemia and myelodysplastic syndrome are life-threatening bone marrow disorders with few optimal treatment options. Many patients with these diseases fail conventional therapy. Amongst those with severe AA who respond to conventional treatment, up to 30 percent will suffer relapse or evolve to myelodysplastic syndrome or leukemia which is often fatal,” said Dr. Childs.

“Promising preclinical and clinical data have shown the efficacy of Gamida Cell’s ex-vivo hematopoietic stem cell technology. Based upon exciting prior data, we are now conducting a clinical trial at the NHLBI testing whether umbilical cord blood transplantation using CordIn can be used to improve the results of conventional cord blood transplantation for patients with these life-threatening conditions who lack an available matched donor,” he added.

The study is titled “Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome.” The primary endpoint of the Phase 1/2 trial is prompt and durable cord engraftment in patients transplanted with CordIn.

CordIn is produced by Gamida Cell, which focuses on cellular and immune therapies for the treatment of cancer and orphan genetic diseases.CordIn is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.